Active targeted ligand-aza-BODIPY conjugate for near-infrared photodynamic therapy in melanoma

Volume: 579, Pages: 119189 - 119189
Published: Apr 1, 2020
Abstract
Active targeting compound, a non-iodinated derivative of IK-IK-I2-azaBODIPY (1a) was previously reported to preferentially bind melanoma over healthy cells. In this study, we evaluate the photodynamic therapy (PDT) efficiency on melanoma cells of 1a, together with its reversed sequence compound KI-KI-I2-azaBODIPY (1b) and a non-targeted control I2-azaBODIPY-NH2 (2). All three test compounds possess absorption wavelengths in the near-infrared...
Paper Details
Title
Active targeted ligand-aza-BODIPY conjugate for near-infrared photodynamic therapy in melanoma
Published Date
Apr 1, 2020
Volume
579
Pages
119189 - 119189
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.